Preferences help
enabled [disable] Abstract
Number of results
2014 | 61 | 3 | 505-508
Article title

Influenza viruses resistant to neuraminidase inhibitors

Title variants
Languages of publication
Neuraminidase inhibitors (NAIs) are antiviral drugs for treatment and prophylaxis of influenza. By blocking the activity of the enzyme neuraminidase, NAIs prevent new viral particles from being released. The increasing use of NAIs brings into focus the risk of drug resistance arising to the class. There are three levels of antiviral resistance according to the way that resistance can be detected or inferred: genotypic, phenotypic and clinical resistance. For many years seasonal influenza viruses resistance to NAIs was low (0.33%). Recently, there has been described an increasing number of resistant seasonal influenza strains to oseltamivir (2% in adults, 5-18% in children). In 2007 there were published data describing 14% resistant to oseltamivir strains of influenza A/H1N1/ in Europe. Approximately 0.5-1.0% of influenza A/H1N1/pdm09 isolates are currently resistant to oseltamivir. The established markers of the resistance to oseltamivir were found in 2.4% of human and 0.8% of avian isolates of influenza A/H5N1/. It has been not observed a cross resistance among oseltamivir and zanamivir. NAIs resistance in influenza viruses is relative and despite its presence patients with resistant viruses may still benefit from receiving these antivirals. The response to treatment with antivirals remains the most important proof of antiviral effectiveness. The rational use of NAIs is essential to preserve the best choice for treatment and prophylaxis of seasonal, avian and pandemic influenza.
Physical description
  • Department of Family Medicine, Warsaw Medical University, Warsaw, Poland
  • Department of Influenza Research, National Influenza Center, National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland
  • Advisory Committee on Immunization Practices (ACIP) (2014) Prevention and Control of Seasonal Influenza with Vaccines. Recommendations of the Advisory Committee on Immunization Practices-United States, 2013-14.
  • Chotpitayasununondh T, Ungchusak K, Hanshaoworakuln W, et al. (2005) Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 11: 201-209.
  • European Medicines Agency (EMA) (2013) Updated review of influenza antiviral medicinal products for potential use during pandemic by the Committee for Medical Products for Human Use (CHMP) of the European Medicine Agency. (accessed 12 April 2013).
  • Govorkova E, Baranovich T, Seiler P, Armstrong J, Burnham A, Guan Y, Peiris M, Webby R, Webster R, (2013) Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antiviral Research 98: 297-304.
  • Gubareva LV (2004) Molecular mechanisms of influenza viruses resistance to neuraminidase inhibitors. Virus Res 103: 199-203.
  • Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC (1998) Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 178: 1257-1262.
  • Hayden FG, Gubereva LV, Monto AS, et al. (2000) Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 343: 1282-1289.
  • Hayden FG, Belshe R, Villanueva C (2004) Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without post-exposure prophylaxis. J Infect Dis 189: 440-449.
  • Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, Phuah SP, Caldwell N, Freeman K, Komadina N, Smith D, Speers D, Kelso A, Lin RT, Maurer-Stroh S, Barr IG (2011) Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation Euro Surveill 16: pii: 19884.
  • de Jong MD, Tran TT, Troung HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
  • Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, Zambon MC (2008) Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Euro Surveill 13: 1-3.
  • Le Q, Kiso M, Someya K, Sakai T, Nguen T, Ngyuen K, Pham N, et al. (2005) Avian flu: isolation of drug resistant H5N1 virus. Nature 437: 1108.
  • McKimm-Breschkin JL (2000) Resistance of influenza viruses to neuraminidase inhibitors. Antiviral Res 47: 1-17.
  • McKimm-Breschkin JL, Williams J, Barrett S, Jachno K, McDonald M, Mohr PG, Saito T, Tashiro M (2013) Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J Antimicrob Chemother 68: 2210-2221.
  • Monto AS, Fleming DM, Henry D (1999) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infection. J Infect Dis 180: 254-261.
  • Monto AS, McKimm-Breschkin JL, Macken C, Hampson A, Hay A (2006) Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50: 2395-2402.
  • Moscona A (2005) Neuraminidase inhibitors for influenza. New Engl J Med 353: 1363-7134.
  • Nicholson KG, Aoki FY, Osterhaus AD (2000) Efficacy and safety of oseltamivir in treatment of acute influenza a randomized controlled trial. Lancet 355: 1845-1850.
  • Nicoll A, Ciancio B, Kramarz P (2008) Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential implications. Euro Surveill 13: 3-6.
  • Okomo-Adhiambo M, Sleeman K, Lysen C, Nguyen XT, Xu X, Klimov AI, Gubareva LV (2013) Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during 2011 Southern Hemisphere season. Influenza Other Respir Viruses 7: 645-658.
  • Reece PA (2007) Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 79: 1577-1586.
  • Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva LV (2013) R292K substitution and drug susceptibility of influenza A (H7N9) viruses. Emerg Infect Dis 19: 1521-1524.
  • Thorlund K, Awad T, Boivin G, Thabane L (2011) Systematic review of inf.luenza resistance to the neuraminidase inhibitors. BMC Infect Dis 11: 134-142.
  • Tran TH, Nguen TL, Luong TS, Pham PM et al. (2004) Avian influenza A (h5N1) in 10 patients in Vietnam. N Engl J Med 350: 1179-1188.
  • Treanor JJ, Hayden FG, Vrooman PS (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283: 1016-1024.
  • Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL, Colman PM (1998) Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6: 735-746.
  • Ward P, Small I, Smith JM, Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an avian influenza pandemic. J Antimicrob Chemother 55: i5-25.
  • Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20: 127-133.
  • World Health Organization (WHO) (2014) Issues new guidelines for the avian flu virus.
  • World Health Organization (WHO) (2007) Avian influenza situation in Egypt - update, 18 January 2007.
  • Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, Govorkova E (2006) Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 80: 8787-8795.
  • Yen HL, Monto AS, Webster RG, Govorkova EA (2001) Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A /Vietnam/1203/04 influenza virus in mice. Antimicrob Agents Chemother 192: 665-672.
  • Yuen KY, Wong SS (2005) Human infection by avian influenza A H5N1. Hong Kong Med J 11: 189-199.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.